APA (7th ed.) Citation

C, P., FH, S., DA, C., LJ, W., F, D., O, N., . . . PG, R. (2024). Progression-free survival as a surrogate endpoint in myeloma clinical trials: An evolving paradigm. Blood cancer journal, 14(1), 134. https://doi.org/10.1038/s41408-024-01109-4

Chicago Style (17th ed.) Citation

C, Pawlyn, et al. "Progression-free Survival as a Surrogate Endpoint in Myeloma Clinical Trials: An Evolving Paradigm." Blood Cancer Journal 14, no. 1 (2024): 134. https://doi.org/10.1038/s41408-024-01109-4.

MLA (9th ed.) Citation

C, Pawlyn, et al. "Progression-free Survival as a Surrogate Endpoint in Myeloma Clinical Trials: An Evolving Paradigm." Blood Cancer Journal, vol. 14, no. 1, 2024, p. 134, https://doi.org/10.1038/s41408-024-01109-4.